Amarin has forged a licensing deal with Italian pharma Recordati to commercialize its fish oil-derived heart pill Vascepa. Recordati will pay Amarin $25 million upfront to market the product to 59 European countries. More: Amarin sells heart pill Vascepa's rights
read more
Enter this year’s famous competition More: 2025 PharmaTimes Clinical Researcher of the Year Source: News
read moreThe Bloc is building out its European presence, as the New York-based independent health agency announced Tuesday the formation of its first London outpost. More: London calling: The Bloc expands into UK with new office, executive hires Source: fierce
read moreSen. Bill Cassidy, M.D., R-La., has come out critical of Robert F. Kennedy Jr.’s picks for the CDC’s vaccine advisory panel, calling for the committee’s upcoming meeting to be postponed. More: Cassidy, key in RFK Jr.'s HHS confirmation, calls for
read moreThe FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. More: AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset Source:
read morePublicis Health has snapped up another Omnicom Health Group executive. Six months after Matt McNally took up the global CEO post at Publicis, Craig Romanok has landed the chief commercial officer position at the agency’s Digitas Health unit. More: Craig
read more© 1994 - 2026 B.M. Pharmaceuticals